|Advaxis’ Cervical Cancer Treatment Trial Shows Progress in Survival Rate|
|By FDAnews Drug Daily Bulletin|
|Saturday, 26 September 2015 00:57|
A trial of a cervical cancer treatment by New Jersey biotech company Advaxis demonstrated it could extend life further than existing treatments in women with persistent, advanced forms of the disease.
Among the high-risk patients placed on the immunotherapy therapy axalimogene filolisbac and studied through a one-year period, there was a 38.5 percent survival rate, the company said last week.
Conducted by the nonprofit Gynecologic Oncology Group, the first-stage of the Phase 2 trial monitored how three doses administered over three months influenced the health of 26 patients who had not improved with other treatment options.
Many of the women (73 percent) experienced low-grade safety concerns — mostly fatigue, chills and fever. Four patients had more serious health risks, including hypotension and cytokine release syndrome, and one fell ill with a lung infection and sepsis.